ERBB2 and gastric cancer: Confirmed primary tumor types at enrollment were ESCC [n = 2 (17%)], SCCHN [n = 2 (17%)], HER2-overexpressing breast cancer [n = 6 (50%)], and HER2-overexpressing gastric cancer [n = 2 (17%)].